{"entity":{"id":"genomefrontier-therapeutics","kind":"company","name":"GenomeFrontier Therapeutics","aka":[],"tldr":"GenomeFrontier Therapeutics makes CAR T-cell therapies, in which a patient's own immune cells are engineered to attack cancer, using a method that does not need a virus to carry the new gene. Its first product targets two markers on B-cell lymphoma cells.","summary":"GenomeFrontier Therapeutics, headquartered in Xizhi District, New Taipei City, Taiwan, develops CAR T and TCR T cell therapies with its Quantum Engine system, which combines four virus-free gene and cell engineering platforms including a piggyBac-based vector (Quantum pBac) and a delivery method it calls Quantum Nufect. Its lead product GF-CART01 is a dual-targeting CD20/CD19 CAR T with a safety switch, in a phase 1 3+3 dose-escalation study (NCT06703892) in relapsed or refractory B-cell haematological malignancies including diffuse large B-cell, follicular and primary mediastinal large B-cell lymphoma, at a site in Taipei. GF-CART02 targets multiple myeloma and GF-CART03 is an armoured multi-target CAR T for solid tumours. Its first registered cancer trial, NCT06703892, was posted on ClinicalTrials.gov in November 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://genomefrontier.com/"},{"label":"Pipeline","url":"https://genomefrontier.com/pipeline/"},{"label":"ClinicalTrials.gov: phase 1 trial of GF-CART01 (NCT06703892)","url":"https://clinicaltrials.gov/study/NCT06703892"}],"tags":[],"related":[],"cancers":["dlbcl","follicular-lymphoma","primary-mediastinal-b-cell-lymphoma"],"sections":["cell-therapy"],"technologies":["car-t","car-t-manufacturing-process"],"targets":["cd19","cd20"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the pages read on 29 October 2026.","The trial sponsor is GenomeFrontier Therapeutics TW Co., Ltd.; the website is that of GenomeFrontier Therapeutics, CORP.","No financing round is recorded."],"hq":"New Taipei City","country":"TW","companyType":"cell-therapy","website":"https://genomefrontier.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/genomefrontier-therapeutics/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"car-t-manufacturing-process","kind":"technology","name":"Autologous CAR-T manufacturing, batch by batch","route":"/technologies/car-t-manufacturing-process/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}]}}